The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Reed Elizabeth E since 2006.
This trader's CIK number is 1283303.
At the time of last reporting, Reed Elizabeth E was the Chief Legal Officer and GC of Travere Therapeutics, Inc.. (stock ticker symbol TVTX).
Also see all insider trading activities at Travere Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | TVTX | 0 | $0 | 24,308 | $516,280 | 12,920 | $0 |
| 2024 | TVTX | 0 | $0 | 11,213 | $110,440 | 0 | $0 |
| 2023 | TVTX | 0 | $0 | 5,230 | $98,011 | 0 | $0 |
| 2022 | TVTX | 0 | $0 | 10,550 | $272,138 | 0 | $0 |
| 2021 | TVTX | 0 | $0 | 16,883 | $454,874 | 0 | $0 |
| 2020 | TVTX | 0 | $0 | 14,577 | $274,787 | 0 | $0 |
| 2019 | TVTX | 0 | $0 | 4,319 | $92,474 | 0 | $0 |
| 2018 | TVTX | 0 | $0 | 5,942 | $144,430 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2006 | ANDS | 0 | $0 | 4,500 | $51,826 | 4,500 | $13,275 |
1. Travere Therapeutics, Inc. (TVTX)
2. Anadys Pharmaceuticals Inc (ANDS)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-05 | TVTX | Sale | 4,920 | 21.05 | 103,566 |
| 2025-05-02 | TVTX | Option Ex | 4,920 | .00 | 0 |
| 2025-02-10 | TVTX | Option Ex | 8,000 | .00 | 0 |
| 2025-02-12 | TVTX | Sale | 8,000 | 23.53 | 188,240 |
| 2025-02-03 | TVTX | Sale | 8,951 | 19.78 | 177,050 |
| 2025-01-22 | TVTX | Sale | 2,437 | 19.46 | 47,424 |
| 2024-09-09 | TVTX | Sale | 4,387 | 11.52 | 50,538 |
| 2024-02-01 | TVTX | Sale | 4,764 | 8.70 | 41,427 |
| 2024-01-23 | TVTX | Sale | 2,062 | 8.96 | 18,475 |
| 2023-09-05 | TVTX | Sale | 1,815 | 14.71 | 26,698 |
| 2023-05-10 | TVTX | Sale | 825 | 16.59 | 13,686 |
| 2023-02-01 | TVTX | Sale | 2,590 | 22.25 | 57,627 |
| 2022-05-12 | TVTX | Sale | 1,050 | 21.51 | 22,584 |
| 2022-05-10 | TVTX | Sale | 900 | 21.51 | 19,359 |
| 2022-01-31 | TVTX | Sale | 1,350 | 27.40 | 36,990 |
| 2022-01-24 | TVTX | Sale | 2,250 | 24.98 | 56,205 |
| 2022-01-11 | TVTX | Sale | 5,000 | 27.40 | 137,000 |
| 2021-08-17 | TVTX | Sale | 1,407 | 17.12 | 24,086 |
| 2021-05-11 | TVTX | Sale | 1,625 | 19.14 | 31,102 |
| 2021-05-12 | TVTX | Sale | 1,625 | 19.46 | 31,622 |
| 2021-02-05 | TVTX | Sale | 2,250 | 31.41 | 70,672 |
| 2021-02-08 | TVTX | Sale | 2,250 | 31.58 | 71,055 |
| 2021-02-03 | TVTX | Sale | 3,175 | 28.91 | 91,789 |
| 2021-02-02 | TVTX | Sale | 3,175 | 30.75 | 97,631 |
| 2021-01-06 | TVTX | Sale | 688 | 27.01 | 18,582 |
| 2021-01-05 | TVTX | Sale | 688 | 26.65 | 18,335 |
| 2020-11-16 | RTRX | Sale | 2,500 | 23.98 | 59,950 |
| 2020-11-13 | RTRX | Sale | 2,500 | 23.62 | 59,045 |
| 2020-09-23 | RTRX | Sale | 1,500 | 18.48 | 27,720 |
| 2020-09-22 | RTRX | Sale | 1,500 | 18.59 | 27,885 |
| 2020-05-11 | RTRX | Sale | 525 | 14.95 | 7,848 |
| 2020-05-12 | RTRX | Sale | 1,052 | 17.07 | 17,959 |
| 2020-03-10 | RTRX | Sale | 3,500 | 15.02 | 52,570 |
| 2020-01-07 | RTRX | Sale | 750 | 13.94 | 10,455 |
| 2020-01-08 | RTRX | Sale | 750 | 15.14 | 11,355 |
| 2019-05-14 | RTRX | Sale | 525 | 17.75 | 9,318 |
| 2019-05-15 | RTRX | Sale | 525 | 17.71 | 9,297 |
| 2019-02-12 | RTRX | Sale | 884 | 21.50 | 19,006 |
| 2019-02-11 | RTRX | Sale | 885 | 21.38 | 18,921 |
| 2019-01-08 | RTRX | Sale | 750 | 24.09 | 18,067 |
| 2019-01-09 | RTRX | Sale | 750 | 23.82 | 17,865 |
| 2018-11-14 | RTRX | Sale | 2,500 | 24.09 | 60,235 |
| 2018-11-15 | RTRX | Sale | 2,500 | 24.62 | 61,550 |
| 2018-01-05 | RTRX | Sale | 942 | 24.04 | 22,645 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2006-04-10 | ANDS | Sale | 1,500 | 13.71 | 20,559 |
| 2006-04-10 | ANDS | Option Ex | 1,500 | 2.95 | 4,425 |
| 2006-02-13 | ANDS | Option Ex | 1,500 | 2.95 | 4,425 |
| 2006-02-13 | ANDS | Sale | 1,500 | 10.84 | 16,252 |
| 2006-01-09 | ANDS | Sale | 1,500 | 10.01 | 15,015 |
| 2006-01-09 | ANDS | Option Ex | 1,500 | 2.95 | 4,425 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Reed Elizabeth E (Chief Legal Officer and GC of Travere Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.